Selected research
Industry Research
Sphingosine-1-Receptor Modulators Drugs Industry Research Report 2026
Market perspective
The global Sphingosine-1-Receptor Modulators Drugs market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Sphingosine-1-Receptor Modulators Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Sphingosine-1-Receptor Modulators Drugs is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Sphingosine-1-Receptor Modulators Drugs is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Sphingosine-1-Receptor Modulators Drugs include Sun Pharma, Johnson & Johnson, Novartis, Idorsia, HEC Pharm Co. Limited, Bristol-Myers Squibb, Biocon and Arena Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Sphingosine-1-Receptor Modulators Drugs market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Sphingosine-1-Receptor Modulators Drugs Market by Company
Sun Pharma
Johnson & Johnson
Novartis
Idorsia
HEC Pharm Co. Limited
Bristol-Myers Squibb
Biocon
Arena Pharmaceuticals
Sphingosine-1-Receptor Modulators Drugs Segment by Type
Siponimod
Fingolimod
Ozanimod
Other
Sphingosine-1-Receptor Modulators Drugs Segment by Application
Hospital
Clinic
Other
Sphingosine-1-Receptor Modulators Drugs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Sphingosine-1-Receptor Modulators Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Sphingosine-1-Receptor Modulators Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Sphingosine-1-Receptor Modulators Drugs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Sphingosine-1-Receptor Modulators Drugs manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Sphingosine-1-Receptor Modulators Drugs by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Sphingosine-1-Receptor Modulators Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Siponimod
- Fingolimod
- Ozanimod
- Other
Applications
- Hospital
- Clinic
- Other
Companies covered
- Sun Pharma
- Johnson & Johnson
- Novartis
- Idorsia
- HEC Pharm Co. Limited
- Bristol-Myers Squibb
- Biocon
- Arena Pharmaceuticals
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Sphingosine-1-Receptor Modulators Drugs Market Size (2021-2032)
- 2.2.2 Global Sphingosine-1-Receptor Modulators Drugs Sales (2021-2032)
- 2.2.3 Global Sphingosine-1-Receptor Modulators Drugs Market Average Price (2021-2032)
- 2.3 Sphingosine-1-Receptor Modulators Drugs by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Siponimod
- 2.3.3 Fingolimod
- 2.3.4 Ozanimod
- 2.3.5 Other
- 2.4 Sphingosine-1-Receptor Modulators Drugs by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Hospital
- 2.4.3 Clinic
- 2.4.4 Other
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Sphingosine-1-Receptor Modulators Drugs Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Sphingosine-1-Receptor Modulators Drugs Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Sphingosine-1-Receptor Modulators Drugs Revenue of Manufacturers (2021-2026)
- 3.4 Global Sphingosine-1-Receptor Modulators Drugs Average Price by Manufacturers (2021-2026)
- 3.5 Global Sphingosine-1-Receptor Modulators Drugs Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Sphingosine-1-Receptor Modulators Drugs, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Sphingosine-1-Receptor Modulators Drugs, Product Type & Application
- 3.8 Global Manufacturers of Sphingosine-1-Receptor Modulators Drugs, Established Date
- 3.9 Global Sphingosine-1-Receptor Modulators Drugs Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Sun Pharma
- 4.1.1 Sun Pharma Company Information
- 4.1.2 Sun Pharma Business Overview
- 4.1.3 Sun Pharma Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Sun Pharma Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.1.5 Sun Pharma Recent Developments
- 4.2 Johnson & Johnson
- 4.2.1 Johnson & Johnson Company Information
- 4.2.2 Johnson & Johnson Business Overview
- 4.2.3 Johnson & Johnson Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Johnson & Johnson Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.2.5 Johnson & Johnson Recent Developments
- 4.3 Novartis
- 4.3.1 Novartis Company Information
- 4.3.2 Novartis Business Overview
- 4.3.3 Novartis Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Novartis Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.3.5 Novartis Recent Developments
- 4.4 Idorsia
- 4.4.1 Idorsia Company Information
- 4.4.2 Idorsia Business Overview
- 4.4.3 Idorsia Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Idorsia Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.4.5 Idorsia Recent Developments
- 4.5 HEC Pharm Co. Limited
- 4.5.1 HEC Pharm Co. Limited Company Information
- 4.5.2 HEC Pharm Co. Limited Business Overview
- 4.5.3 HEC Pharm Co. Limited Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 HEC Pharm Co. Limited Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.5.5 HEC Pharm Co. Limited Recent Developments
- 4.6 Bristol-Myers Squibb
- 4.6.1 Bristol-Myers Squibb Company Information
- 4.6.2 Bristol-Myers Squibb Business Overview
- 4.6.3 Bristol-Myers Squibb Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Bristol-Myers Squibb Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.6.5 Bristol-Myers Squibb Recent Developments
- 4.7 Biocon
- 4.7.1 Biocon Company Information
- 4.7.2 Biocon Business Overview
- 4.7.3 Biocon Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Biocon Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.7.5 Biocon Recent Developments
- 4.8 Arena Pharmaceuticals
- 4.8.1 Arena Pharmaceuticals Company Information
- 4.8.2 Arena Pharmaceuticals Business Overview
- 4.8.3 Arena Pharmaceuticals Sphingosine-1-Receptor Modulators Drugs Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Arena Pharmaceuticals Sphingosine-1-Receptor Modulators Drugs Product Portfolio
- 4.8.5 Arena Pharmaceuticals Recent Developments
5 Global Sphingosine-1-Receptor Modulators Drugs Market Scenario by Region
- 5.1 Global Sphingosine-1-Receptor Modulators Drugs Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Sphingosine-1-Receptor Modulators Drugs Sales by Region: 2021-2032
- 5.2.1 Global Sphingosine-1-Receptor Modulators Drugs Sales by Region: 2021-2026
- 5.2.2 Global Sphingosine-1-Receptor Modulators Drugs Sales by Region: 2027-2032
- 5.3 Global Sphingosine-1-Receptor Modulators Drugs Revenue by Region: 2021-2032
- 5.3.1 Global Sphingosine-1-Receptor Modulators Drugs Revenue by Region: 2021-2026
- 5.3.2 Global Sphingosine-1-Receptor Modulators Drugs Revenue by Region: 2027-2032
- 5.4 North America Sphingosine-1-Receptor Modulators Drugs Market Facts & Figures by Country
- 5.4.1 North America Sphingosine-1-Receptor Modulators Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Sphingosine-1-Receptor Modulators Drugs Sales by Country (2021-2032)
- 5.4.3 North America Sphingosine-1-Receptor Modulators Drugs Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Sphingosine-1-Receptor Modulators Drugs Market Facts & Figures by Country
- 5.5.1 Europe Sphingosine-1-Receptor Modulators Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Sphingosine-1-Receptor Modulators Drugs Sales by Country (2021-2032)
- 5.5.3 Europe Sphingosine-1-Receptor Modulators Drugs Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Sphingosine-1-Receptor Modulators Drugs Market Facts & Figures by Country
- 5.6.1 Asia Pacific Sphingosine-1-Receptor Modulators Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Sphingosine-1-Receptor Modulators Drugs Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Sphingosine-1-Receptor Modulators Drugs Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Sphingosine-1-Receptor Modulators Drugs Market Facts & Figures by Country
- 5.7.1 South America Sphingosine-1-Receptor Modulators Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Sphingosine-1-Receptor Modulators Drugs Sales by Country (2021-2032)
- 5.7.3 South America Sphingosine-1-Receptor Modulators Drugs Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Sphingosine-1-Receptor Modulators Drugs Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Sphingosine-1-Receptor Modulators Drugs Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Sphingosine-1-Receptor Modulators Drugs Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Sphingosine-1-Receptor Modulators Drugs Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Sphingosine-1-Receptor Modulators Drugs Sales by Type (2021-2032)
- 6.1.1 Global Sphingosine-1-Receptor Modulators Drugs Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Sphingosine-1-Receptor Modulators Drugs Sales Market Share by Type (2021-2032)
- 6.2 Global Sphingosine-1-Receptor Modulators Drugs Revenue by Type (2021-2032)
- 6.2.1 Global Sphingosine-1-Receptor Modulators Drugs Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Sphingosine-1-Receptor Modulators Drugs Revenue Market Share by Type (2021-2032)
- 6.3 Global Sphingosine-1-Receptor Modulators Drugs Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Sphingosine-1-Receptor Modulators Drugs Sales by Application (2021-2032)
- 7.1.1 Global Sphingosine-1-Receptor Modulators Drugs Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Sphingosine-1-Receptor Modulators Drugs Sales Market Share by Application (2021-2032)
- 7.2 Global Sphingosine-1-Receptor Modulators Drugs Revenue by Application (2021-2032)
- 7.2.1 Global Sphingosine-1-Receptor Modulators Drugs Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Sphingosine-1-Receptor Modulators Drugs Revenue Market Share by Application (2021-2032)
- 7.3 Global Sphingosine-1-Receptor Modulators Drugs Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Sphingosine-1-Receptor Modulators Drugs Value Chain Analysis
- 8.1.1 Sphingosine-1-Receptor Modulators Drugs Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Sphingosine-1-Receptor Modulators Drugs Production Mode & Process
- 8.2 Sphingosine-1-Receptor Modulators Drugs Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Sphingosine-1-Receptor Modulators Drugs Distributors
- 8.2.3 Sphingosine-1-Receptor Modulators Drugs Customers
9 Global Sphingosine-1-Receptor Modulators Drugs Analyzing Market Dynamics
- 9.1 Sphingosine-1-Receptor Modulators Drugs Industry Trends
- 9.2 Sphingosine-1-Receptor Modulators Drugs Industry Drivers
- 9.3 Sphingosine-1-Receptor Modulators Drugs Industry Opportunities and Challenges
- 9.4 Sphingosine-1-Receptor Modulators Drugs Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst